Aprea reports preliminary Phase 1 safety data for WEE1 inhibitor APR-1051; no hematologic toxicity

Aprea Therapeutics, Inc.

APR-1051 safe and well-tolerated in first three patients; all adverse events Grade 1-2, no neutropenia or QT prolongation.
Phase 1 ACESOT-1051 study evaluating 10–150 mg daily doses; 8 cohorts planned, subtherapeutic doses given in cohorts 1-3.
Data cutoff Oct 7, 2024: one patient progressed at 49 days, one withdrew at 36 days, third continues on treatment.
Active enrollment at 3 U.S. sites (NEXT Oncology in San Antonio & Dallas, MD Anderson); preliminary efficacy data expected in 2025.
APR-1051 designed for selective WEE1 inhibition without PLK off-target effects seen with other WEE1 inhibitors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.